195 related articles for article (PubMed ID: 36915979)
1. Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors.
Society of Obstetrics and Gynecology of Zhejiang Medical Association ; Society of Urology of Zhejiang Medical Association ; Committee of Breast Cancer of Zhejiang Anticancer Association ; Committee of Clinical Pharmacy on Oncology of Zhejiang Anticancer Association (preparation) ; Committee of Urology of Zhejiang Society for Mathematical Medicine
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):765-774. PubMed ID: 36915979
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
4. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
5. Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.
Friedlander M; Lee YC; Tew WP
Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e390876. PubMed ID: 37285556
[TBL] [Abstract][Full Text] [Related]
6. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
7. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract][Full Text] [Related]
9. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.
Vilchez Larrea SC; Haikarainen T; Narwal M; Schlesinger M; Venkannagari H; Flawiá MM; Villamil SH; Lehtiö L
PLoS One; 2012; 7(9):e46063. PubMed ID: 23049934
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E; Bataller A; Urrutia S; Gener-Ricos G; Briski RE; Kanagal-Shamanna R; Lu KH; Westin SN; Yap TA; Takahashi K; Ravandi F; Alvarado Y; Kadia T; Sasaki K; Kantarjian HM; Garcia-Manero G
Br J Haematol; 2023 May; 201(3):e25-e29. PubMed ID: 36951293
[No Abstract] [Full Text] [Related]
13. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
14. Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
Girard S; Lours C
Am J Hematol; 2023 Oct; 98(10):1665-1666. PubMed ID: 37226864
[No Abstract] [Full Text] [Related]
15. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Jonuscheit S; Jost T; Gajdošová F; Wrobel M; Hecht M; Fietkau R; Distel L
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073147
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
18. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
20. Adverse events of PARP inhibitors.
Romanová Martina; Klát Jaroslav
Ceska Gynekol; 2021; 86(1):54-60. PubMed ID: 33752410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
